Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125682091 | 12568209 | 1 | I | 20151201 | 20160707 | 20160718 | 20160718 | EXP | GB-MHRA-EYC 00141824 | GB-TEVA-676404ACC | TEVA | 34.00 | YR | M | Y | 80.00000 | KG | 20160719 | CN | GB | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125682091 | 12568209 | 1 | PS | PAROXETINE HYDROCHLORIDE. | PAROXETINE HYDROCHLORIDE | 1 | Oral | TAPERED FROM 40MG TO ZERO IN SIX WEEKS | U | 76618 | 40 | MG | ORAL SOLUTION | ||||||
125682091 | 12568209 | 2 | C | CYCLIZINE HYDROCHLORIDE | CYCLIZINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
125682091 | 12568209 | 3 | C | FORTISIP | CARBOHYDRATESFATTY ACIDSMINERALSPROTEINVITAMINS | 1 | 0 | ||||||||||||
125682091 | 12568209 | 4 | C | GAVISCON ADVANCE | POTASSIUM BICARBONATESODIUM ALGINATE | 1 | 0 | ||||||||||||
125682091 | 12568209 | 5 | C | IBUPROFEN. | IBUPROFEN | 1 | 0 | ||||||||||||
125682091 | 12568209 | 6 | C | 5-HYDROXYTRYPTOPHAN | OXITRIPTAN | 1 | 0 | ||||||||||||
125682091 | 12568209 | 7 | C | MAGNESIUM | MAGNESIUM | 1 | 0 | ||||||||||||
125682091 | 12568209 | 8 | C | OMEGA-3 FISH OIL | FISH OILOMEGA-3 FATTY ACIDS | 1 | 0 | ||||||||||||
125682091 | 12568209 | 9 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 0 | ||||||||||||
125682091 | 12568209 | 10 | C | TEVA UK PROPRANOLOL | 2 | 0 | |||||||||||||
125682091 | 12568209 | 11 | C | VITAMIN B COMPLEX STRONG | 2 | 0 | |||||||||||||
125682091 | 12568209 | 12 | C | VITAMIN C | ASCORBIC ACID | 1 | 0 | ||||||||||||
125682091 | 12568209 | 13 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125682091 | 12568209 | 1 | Depression |
125682091 | 12568209 | 2 | Nausea |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125682091 | 12568209 | LT |
125682091 | 12568209 | HO |
125682091 | 12568209 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125682091 | 12568209 | Agitation | |
125682091 | 12568209 | Anger | |
125682091 | 12568209 | Anxiety | |
125682091 | 12568209 | Back pain | |
125682091 | 12568209 | Chest pain | |
125682091 | 12568209 | Chills | |
125682091 | 12568209 | Condition aggravated | |
125682091 | 12568209 | Decreased appetite | |
125682091 | 12568209 | Depression | |
125682091 | 12568209 | Dizziness | |
125682091 | 12568209 | Dyschromatopsia | |
125682091 | 12568209 | Dyskinesia | |
125682091 | 12568209 | Hyperacusis | |
125682091 | 12568209 | Hyperhidrosis | |
125682091 | 12568209 | Hypersensitivity | |
125682091 | 12568209 | Hypervigilance | |
125682091 | 12568209 | Hypoaesthesia | |
125682091 | 12568209 | Insomnia | |
125682091 | 12568209 | Mood swings | |
125682091 | 12568209 | Palpitations | |
125682091 | 12568209 | Peripheral coldness | |
125682091 | 12568209 | Photophobia | |
125682091 | 12568209 | Rash | |
125682091 | 12568209 | Salivary hypersecretion | |
125682091 | 12568209 | Suicidal ideation | |
125682091 | 12568209 | Thirst | |
125682091 | 12568209 | Vertigo | |
125682091 | 12568209 | Visual impairment | |
125682091 | 12568209 | Vomiting | |
125682091 | 12568209 | Withdrawal syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125682091 | 12568209 | 1 | 19981201 | 20151201 | 0 |